Carboplatin-induced hematuria in a patient of breast carcinoma. A case report.
Platinum-based antineoplastic drugs are widely used in the treatment of solid tumors. Carboplatin, a second generation platinum compound, was developed to have less nonhematologic toxicity, in comparison with cisplatin. We report on a 34-year-old woman with breast cancer who developed gross hematuria after initiation of carboplatin-based chemotherapy. To our knowledge, there are very few cases reports of carboplatin-associated gross hematuria.
Taj
Asma
A
Department of Medicine, University of Toledo, OH 43614, USA. asma.taj@utoledo.edu
Vijendra
Divya
D
Shafiq
Qaiser
Q
Mohamed
Iman
I
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D016190:Carboplatin / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy; D005260:Female; D006417:Hematuria / Q000139:chemically induced*; D006801:Humans
D000970:Antineoplastic Agents; D016190:Carboplatin